INFORMATION ABOUT ENDO-BIO-THERAPY

1/ the relentless fight against this new ecological, effective and non-toxic medicine

Dr. Trotta has had the immense honor and privilege of working with Dr. Michel Geffard for the last three years of his practice from 2016 to 2019.

This exceptional doctor and researcher has devoted his entire scientific career to finding the causes of chronic diseases and proposing new, less toxic and more effective treatments.

His research has focused in particular on Multiple Sclerosis (MS). In collaboration with hospital neurologists in Bordeaux, who entrusted him with the sera of their patients suffering from this disease, Dr Michel Geffard was able to show that the blood of these patients contained antibodies against neurotransmitters, and that there were fragments of bacteria in their blood, bacteria of intestinal origin leading to a chronic microinfection at the origin of the disease.

Not only was this revolutionary, it would also provide an insight into the pathophysiology of this neurological disease and most other chronic illnesses: intestinal permeability, which leads to chronic infection, oxidation, inflammation and autoimmune reaction, all of which damage the patient’s own organs.

This first revolutionary discovery led to the second, i.e. a treatment adapted to the causes of these diseases. And during this time, Geffard worked relentlessly to develop endo-medicines, new drugs which are part of what would later be called “nano-medicine”, enabling the precise treatment of chronic infection, inflammation, oxidation and autoimmune reaction, without toxicity and with great efficacy.

Unfortunately, and the history of medicine is punctuated by such injustices, these discoveries have created great jealousy and, above all, concern on the part of the multinational drug companies, whose sales of multiple sclerosis have risen from millions of euros to 1 billion euros in the space of 20 years, without any progress being made in the treatment of these patients (with these increasingly expensive treatments, most patients end up almost always in a wheelchair, whereas the opposite was the case with Dr. Geffard’s endotherapy.

What had to happen has happened, because it couldn’t be easier in France: a false denunciation has enabled Dr. Geffard to be struck off the medical register. It’s as if the Ordre des Médecins had disbarred Fleming or Pasteur!

France’s medical association has done itself an injustice and made a fool of itself in the eyes of history, which will recognize Dr. Geffard’s work and, I’m sure, award him the Nobel Prize for Medicine posthumously.

Finally, a cabal set up under Macron and Buzyn in 2019 has indicted Dr. Geffard, the last straw for the illegal practice of medicine, biology and pharmacy! This is what Macron’s France has come to: a France in the hands of the pharmaceutical lobbies, as the Covid crisis has clearly demonstrated, which aims to neutralize an innovative researcher, a humanist doctor who has found a revolutionary treatment for chronic diseases, a treatment that will be recognized in the history of Medicine, whatever their detractors may think.

The Geffard affair is indeed a second Beljanski affair, and bears a striking resemblance to the numerous difficulties and opposition encountered by Dr. Semmelweis when he advocated hand-washing before childbirth in 19th-century Hungary. The medical establishment opposed him with all its might, and for 50 years women continued to die in childbirth despite the discoveries of this innovative doctor. Well, 1 century later, this doctor is recognized as a pioneer, and it will be exactly the same with Dr. Geffard.

As the last of Dr. Geffard’s students, and having received numerous devastated calls and e-mails from patients who had entrusted their health to Dr. Geffard and who could no longer treat themselves because – to add insult to injury – the laboratory of this exceptional researcher was destroyed by the forces of law and order in 2019! – and respecting his Hippocratic oath, Dr. Trotta, in collaboration with Emmanuel Carrrère, a student of Professor Luc Montagnier, the pioneer of Info Medicine who took over the research of Professor Jacques Benvéniste, has developed a digitized version of Dr. Geffard’s endomedicines. And so, in another form, not tablets but digital signals, we can continue the adventure of endobiotherapy until justice or noble and charitable souls take up the torch of this magnificent Medicine.

We will never let our patients down. Our Hippocratic oath is to continue to treat and offer innovative therapies, even if they are opposed and their pioneers hunted down.

It’s up to the French government and the administration to find a legal framework for these endomedicines. Since they don’t want to, under pressure from lobbies that are beyond their control, they are simply forbidding patients to treat themselves with these new treatments, which we remind you are effective and above all non-toxic.

The truth is like water: it will always pass, and history will record the extreme difficulties encountered by endobiotherapy.

“Impossible is not French”: we are proud to continue this fight.

And it’s above all thanks to the support of the many courageous and stubborn patients that we continue this fight, because we work for them and they encourage us.

To find out more about endobiotherapy, you can read the rest of this article and, above all, the short, self-explanatory book that perfectly sums up Dr. Geffard’s 30 years of research and the effectiveness of this treatment on chronic diseases such as multiple sclerosis, Charcot’s disease, cancer and other chronic illnesses.

2/ Helping Dr Geffard in his David vs Goliath battle

An association aims to help Dr. Geffard in his unequal legal battle against the power of the State and the Lobbies. Sick people, patients, friends, we invite you to join this association, and support it financially. The more of us there are, the more likely it is that we’ll be able to bring back and disseminate this wonderful medicine.

3/ Popular article on endotherapy

Latest article in alternative santé magazine, Sept 2019, summarizing the use of endo-bio-therapy to treat chronic illnesses.

4/ Book explaining Endo-Bio-Therapy

Order Dr Trotta’s book published in July 2018

5/ Video on scalar waves and endo-Bio-Therapy

Video explaining endotherapy and scalar waves in chronic diseases: the latest lecture by Dr Trotta at the 6th International Congress on Scalar Waves on Oct 17 and 18, 2019 in Avignon.

If you would like an online consultation or an consultation at his Institute of Natural Medicine in San Sebastian with Dr Trotta, click on the corresponding link.

6/ Summary of the efficacy of endotherapy in 3 chronic diseases that are difficult to cure

3 diagrams are better than a long speech to sum up the effectiveness of this new medicine for serious, chronic illnesses: Here are the comparative, published results of endotherapy versus chemical medicine in 3 of today’s leading diseases: MS (Multiple Sclerosis), metastatic breast cancer and ALS (Amyotrophic Lateral Sclerosis or Charcot’s Disease).

1/MSP: Multiple Sclerosis

The first MS clinical trial (Phase IIa) followed 193 MS patients treated with endotherapy.

This trial showed :

no toxicity,

positive results 25% better than conventional drug therapies

efficacy, since 73% of patients were stabilized or even improved in their secondarily progressive form.

In the graph below :

– in red, MS followed by the chemical treatments of conventional medicine. Worsening is regular and constant, despite increasingly expensive and toxic treatments.

– in blue: follow-up of MS patients treated with endotherapy. There was a clear break in the course of the disease, with disappearance of symptoms, fewer relapses and a marked improvement in the condition of patients treated with endotherapy.

2/ Metastatic breast cancer: comparison between

– patients treated with chemotherapy: lower curve shows a marked increase in mortality, with only 25% of women alive after 5 years

– patients treated with endotherapy: top curve, the survival curve is roughly stabel and over 90% of women are viavante after 5 years.

3/ALS (Amyotrophic Lateral Sclerosis or Charcot’s disease)

We would remind you that there is currently no treatment for this extremely serious disease, in which patients become progressively paralyzed, starting with the hand, then the paralysis spreads and finally leads to respiratory failure after 4 years (left curve).

With the new endotherapy drugs, survival is multiplied by 2, (right curve) from 4 to 8 years.

Developed by Doctor Michel Geffard‘s team*, and used by Doctor Pascal Trotta at his Institut de Médecine Naturelle in San Sebastian, Endo-Bio-Thérapie or multivalent endotherapy is an oral treatment designed to repair lesions caused by radical, inflammatory and infectious aggressions, in chronic pathologies such as cancers, autoimmune diseases and neurodegenerative diseases.

Endo-therapy is indicated for the following diseases: Multiple sclerosis, rheumatoid arthritis, ankylosing spondylitis, Lyme disease, Fibromyalgia, Parkinson’s, Alzheimer’s, hemorrhagic rectocolitis, Crohn’s disease, celiac disease, gluten intolerance, autoimmune thyroiditis, loss of hearing or visual acuity (AMD), dermatological diseases (pemphigus, alopecia, vitiligo, purpuras….), facial neuralgia, trigeminal neuralgia, vascular algias of the face, recurrent urinary tract infections, osteomyelitis (bone infections that are difficult to cure), cancers…

Although they have different genetic causes, chronic diseases share common consequences: oxidation of cellular components, tissue inflammation and activation of the immune system (innate, adaptive).

In all chronic diseases, we find this pathological mechanism: inflammation-oxidation-destruction. Knowing this is essential if you are to heal better without toxic drugs.

Multivalent endotherapy considers that it is more realistic to tackle these consequences by supporting the immune system than to seek to identify all the genes involved in chronic disease.

Fatty acids (omega 3), amino acids and vitamins A, C and E are commonly used to boost natural defenses. Endotherapy uses these compounds by making them stable using a neutral, non-toxic carrier, poly-L-lysine (PLL). Derived from the amino acid lysine, this carrier molecule ensures better availability of vitamins, amino acids and fatty acids: their metabolism is slowed and therapeutic activity is obtained. Thanks to their stability in the body, they can better target and restore lesions. Multivalent endotherapy intervenes at the level of the intestinal barrier, where 70% of immune defenses are located. Current studies demonstrate the involvement of bacteria from the intestinal ecosystem in chronic diseases: the intestinal mucosa becomes permeable to bacterial constituents, and these graft onto anchoring sites (made up of fatty acids) present on healthy cells. The germs then become active, and the immune system can turn against the organism.

Endo-Bio-Therapy uses a decoy effect: by combining fatty acids with poly-L-lysine, it prevents bacteria from attaching themselves to anchoring sites.
This treatment therefore has the effect of attenuating the pathogenic effects generated by the attachment of bacteria to healthy cells.

Dr Michel Geffard’s team has developed compounds with beneficial effects on the blood-brain barrier. Others play an immunomodulatory, anti-allergenic role.
As fatty acids are also highly concentrated in the central nervous system, the treatment compensates for deficiencies that disrupt myelin synthesis and combats inflammatory symptoms, whether in multiple sclerosis, polyarthritis, inflammatory bowel disease, etc… Cell oxidation due to free radicals is dealt with by antioxidants made up of vitamins, amino acids and free-radical scavengers, always linked to poly-L-lysine. These “natural products” are thus able to diffuse throughout the body and be well assimilated before reaching the sites of damage(1).

To protect neurons from toxic molecules and bacterial toxins,
neurotransmitters (derived from amino acids) have been added to facilitate the reconstruction of neuronal circuits.
The protective efficacy of the substance is enhanced, once again, by its binding to poly-L-lysine.
In chronic illnesses, fatty acids, vitamins and amino acids linked to poly-L-lysine act synergistically to support the immune system and restore diminished natural defenses, without toxicity or side effects.

(1)Antioxidants are effective at very low doses, 100 times lower than those usually found in food supplements.

IMMUNOBILANS

To understand inflammatory, autoimmune, degenerative or proliferative mechanisms, research carried out over the last 20 years has enabled us to find immunological indicators: circulating antibodies. They also reveal the induction of radical and degenerative mechanisms through the existence of M-isotype antibodies directed against compounds derived from oxidation and modified antigens.

We therefore perform immunobilans to measure antibody titres.
Between +2 and -2, we are within the norms of the so-called “control” population. On the other hand, when antibody titres exceed +2 or are below -2, we have confirmation of immune system stimulation. The antigens concerned are varied:
– if we have IgM antibodies against fatty acids, lipoperoxidation derivatives or NO, we are in the presence of active inflammatory processes(2);
– if circulating M-isotype antibodies are directed against bacterial constituents, they reveal bacterial-like immune activation(3);
– if we have only A-isotype antibodies against bacterial antigens, we are in the presence of a more progressive form.
Our tests are primarily predictive. In all cases, increased antibodies indicate a progression of the chronic pathology, whether or not the clinical state is disturbed.
We currently perform 6 tests to monitor identified chronic diseases and non-nosologically defined conditions:
1) – evaluation of circulating anti-antigen antibodies modified by NO, NO2 and lipoperoxidation products for indirect identification of radical and oxidative mechanisms;
2) – evaluation of tryptophan-derived anti-antigens (IDO pathway) for indirect identification of toxic and/or immunomodulating products;
3) – determination of antibodies to gram-derived bacterial antigens for identification of chronic bacterial disease and, through the presence of IgA, mucosal hyperpermeability;
4) – determination of anti-mycobacterium tuberculosis (identification of this bacterium in its “latent” state);
5) – determination of anti-antigens associated with malignant cell transformation (cancers, myeloma, etc.)..);
6) – determination of antibodies to non-physiological molecules (contamination due to toxic or medicinal molecules, etc.).

(2)This is very often seen in the relapsing-remitting or worsening phases of MS. (3)In MS, we are dealing with a moderately progressive form.

MAGISTRAL PREPARATIONS

Within the same paradigm, we have developed various therapeutic approaches

The therapies we offer contain PLL-linked fatty acids:

– P0701: lauric, capric, pyruvic and
acids – P0204: myristic, palmitic, oleic, thioctic acids, etc.
– P0705: same fatty acids as P0204, plus amino acids (cysteine PLL, methionine PLL, etc.), vitamins (E PLL, C PLL, etc.), free-radical scavengers (P0201: retinoic acid PLL, CoQ10 PLL, etc.), made therapeutically active by their binding to PLL.

These therapies are beneficial. They have been used by patients for over 15 years. Some ten publications report good results. These therapies have no side effects. They can be combined with other treatments, notably analgesics, etc…
The first clinical trial (phase IIa) in MS showed an absence of toxicity and, at the same time, the beginnings of efficacy, with 73% of patients stabilized or even improved in their secondarily progressive form(4).

These therapies also concern other pathologies, notably cancer: specific preparations help patients to cope better with radiotherapy and chemotherapy.
For each chronic pathology, preparations are adapted.

However, for the past 7 1/2 years, thanks to the support of a pharmacy, patients have been able to obtain magistral preparations prescribed by their doctors.
The immunobilans (or follow-up biological tests) we propose must be performed regularly to readjust the therapy. The clinical situation is also taken into account.

Read the Doctor’s book to find out more?

Consult Doctor Trotta?

Online teleconsultation with the Doctor?

Call the Doctor’s assistant ? Tel 05 54 54 44 43

(4)For the time being, this development, with a view to marketing authorization, has been halted for lack of funding.

PUBLICATIONS ON ENDO-BIO-THERAPY

MANGAS A., COVENAS R., BODET D., DABADIE MP. and GEFFARD M. Evaluation of the effects of a new drug on brain leukocyte infiltration in an experimental model of autoimmune encephalomyelitis. Letters in Drug Design & Discovery (2006) 3(3), 138-148.

MANGAS A., COVENAS R., BODET D., DULEU S., DABADIE M.P., MERCHAN M. and GEFFARD M., GEMSP : A new drug candidate for multiple sclerosis. in : Recent Research Developments in Neurosciences, Research Signpost, Trivandrum-Kerala, India (2007) 2, 93-100.

NICAISE C., COUPIER J., DABADIE M.P., DE DECKER R., MANGAS A., BODET D., PONCELET L., GEFFARD M. and POCHET R. Gemals, a new drug candidate, extends lifespan and improves muscular performance in an amyotrophic lateral sclerosis rat model. Amyotrophic Lateral Sclerosis and other motor neuron disorders (2008) 9(2), 85-90.

MANGAS A., COVENAS R., BODET D., DE LEON M., DULEU S., and GEFFARD M., Evaluation of the effects of a new drug candidate (GEMSP) in a chronic EAE model. Int. J. of Biological Sciences (2008) 4(3), 150-160.

GEFFARD M., PEROTEAU J.F., DULEU S. and DABADIE M.P., Anti-bacterial activity of poly-L-lysine conjugates. BMC Proceedings (2008), 2 (suppl. 1), 22.

MANGAS A., COVENAS R., BODET D., DULEU S. and GEFFARD M., A new drug candidate (GEMSP) for multiple sclerosis. Current Medicinal Chemistry (2009) 16, 3203-3214.

MANGAS A., COVENAS R. and GEFFARD M., New drug therapies for Multiple Sclerosis. Current Opinion in Neurology (2010) 23, 287-292.

GEFFARD M., DE BISSCHOP L., DULEU S., POUNS O., FERRAN G., BESSEDE A., HASSAINE N.,

AUTRAN J.-L., BODET D., MANGAS A., and COVENAS R.,
Endotherapia. Anti-inflammatory and anti-allergy agents in Medicinal Chemistry, Special Issue, BETHAM (ed.) Michigan (2010) 9, N°3. 197-211(15).

GEFFARD M., DE BISSCHOP L., DULEU S., HASSAINE N., MANGAS A. and COVENAS R., Endotherapia: a new frontier in the treatment of multiple sclerosis and other chronic diseases. Discovery Medicine (2011) 10, N°54, 443-451.

COVENAS R., MANGAS A., JAULAIN C. and GEFFARD M., Multiple Sclerosis. In: Molecular and clinical neurosciences. Sugaya K., Samsam M. (eds.), McNeil, Michigan (2010) In press.

GEFFARD M., DULEU S., BESSEDE A., COVENAS R., MANGAS A., A new paradigm for multiple sclerosis. In Multiple sclerosis. A new paradigm. Nova Science Publishers, (2011) in press.

BODET D., MANGAS A., COVENAS R., DABADIE M.P., GEFFARD M., Indirect visualization of specific antigenic modifications induced by nitric oxide in an experimental model of allergic encephalomyelitis. In Multiple sclerosis. A new paradigm. Nova Science Publishers, (2011) in press.

COVENAS R., MANGAS A., DE CASTRO F;, MERCHAN M. GEFFARD M., Immunopathology and immunomodulation in experimental auto immune encephalomyelitis and multiple sclerosis. In Multiple sclerosis. A new paradigm. Nova Science Publishers, (2011) in press.